Europe Launches Personalized Cancer Medicine Initiative

The fight against cancer in Europe has entered a new and ambitious phase with the official launch of the Joint Action on Personalized Cancer Medicine ( JA PCM). This initiative not only aims to improve treatments but also to completely redesign the approach to the disease, placing Aragon at the forefront of European healthcare innovation.

With the participation of 29 European countries and more than 140 partner organizations, this project is coordinated by Sciensano, the Belgian Institute of Public Health. Its mission is clear: to build a sustainable cross-border network that ensures scientific advances translate into fairer, more equitable, and more effective care for all citizens, regardless of where they live.

Through the Aragonese Institute of Health Sciences (IACS), Aragon is becoming a key player in the success of personalized medicine. The region’s contribution focuses on one of the most valuable assets of modern medicine: health data analysis.

The IACS team will use real patient data to determine which diagnostic and therapeutic innovations provide real value to the healthcare system. This approach ensures that clinical decisions are based not only on theories, but also on solid evidence that optimizes resources and improves health outcomes, solidifying the community’s position as a leader in cancer innovation.

A revolution that moves from the laboratory to the consulting room

The essence of personalized medicine is to break with the “one-size-fits-all” model in oncology. It involves adapting prevention, diagnosis, and treatment to the tumor’s genetic profile, the patient’s medical history, and their personal preferences.

“Our main objective is that the genetic revolution does not remain in the laboratory, but that it reaches the consultations of the Aragonese public health system effectively and equitably,” said Juan González, principal investigator of the project at IACS

This commitment seeks to prevent technology from creating new social divides, instead promoting the exchange of good practices to reduce existing inequalities in access to advanced cancer care in Europe.

The seven pillars of oncological transformation

The JA PCM project is structured around pilot projects and practical use cases that will be developed over the next four years. These focus on seven critical areas that will define the future of hospitals:

Risk-based prevention: Implementation of protocols to act before the disease manifests.

Polygenic risk scoring: Using genetics to predict susceptibility to cancer.

Management of genetic predisposition: Comprehensive monitoring of patients with hereditary risk throughout their healthcare journey.

Molecular tumor boards: Improving expert collaboration to decide on the most precise treatments.

Shared treatment models: Generating evidence on new therapies to share risk and innovation.

Liquid biopsy: Use of fluid analysis (blood or urine) to detect tumor DNA and mutations in a minimally invasive way.

Digital innovation: Remote monitoring tools to track the patient’s condition from their home.

To ensure the success of these pilot projects, cross-cutting activities will be carried out, including health technology assessment, training of professionals, and analysis of the ethical, legal, and social implications of these advances.

Beyond healing: the cancer survivor’s quality of life

One of the most innovative aspects of this joint initiative is its focus on continuity of care. Cancer does not end with the final treatment; therefore, the project places special emphasis on life after the disease. Personalized medical follow-up will be promoted for survivors , tailored to their clinical history and individual genetic characteristics.

As Marc Van den Bulcke , coordinator of JA PCM, explains, the goal is “to bridge the gap between research, healthcare systems, and patients’ needs” to achieve optimal benefit. Through this coordinated effort, Europe and Aragon are working to establish a lasting, sustainable, and, above all, person-centered cancer framework.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Gaceta Medica. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.